Virbac (VIRP) Stock Overview
Manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VIRP from our risk checks.
VIRP Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Virbac SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €357.50 |
| 52 Week High | €371.50 |
| 52 Week Low | €249.70 |
| Beta | 0.83 |
| 1 Month Change | 13.49% |
| 3 Month Change | -1.11% |
| 1 Year Change | 1.71% |
| 3 Year Change | 43.29% |
| 5 Year Change | 74.39% |
| Change since IPO | 2,809.33% |
Recent News & Updates
Is There An Opportunity With Virbac SA's (EPA:VIRP) 43% Undervaluation?
Oct 05
Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report
Sep 17There's Reason For Concern Over Virbac SA's (EPA:VIRP) Price
Aug 30Recent updates
Is There An Opportunity With Virbac SA's (EPA:VIRP) 43% Undervaluation?
Oct 05Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report
Sep 17There's Reason For Concern Over Virbac SA's (EPA:VIRP) Price
Aug 30Is There An Opportunity With Virbac SA's (EPA:VIRP) 46% Undervaluation?
Jun 23Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
May 18Virbac (EPA:VIRP) Seems To Use Debt Quite Sensibly
Apr 30
Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals
Strategic R&D investments and facility expansions aim to drive innovation, operational efficiency, and future revenue growth, potentially enhancing profitability.Earnings Not Telling The Story For Virbac SA (EPA:VIRP)
Jan 24An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 47% Undervalued
Oct 06Virbac SA Just Beat Revenue Estimates By 6.0%
Sep 18Unpleasant Surprises Could Be In Store For Virbac SA's (EPA:VIRP) Shares
Aug 31Why We Think Virbac SA's (EPA:VIRP) CEO Compensation Is Not Excessive At All
Jun 15Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Jun 10Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
May 21Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results
Mar 22Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?
Jan 18Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up
Dec 27Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet
Oct 19Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?
Sep 26Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching
Sep 05A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Jun 20Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?
May 31Is Virbac (EPA:VIRP) Using Too Much Debt?
Apr 09Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Feb 28Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 25Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?
Oct 14An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued
Aug 07These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely
Jun 26Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate
May 01We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease
Mar 26Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate
Jan 26Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock
Dec 28A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Oct 27Is Virbac (EPA:VIRP) Using Too Much Debt?
Oct 12Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today
Sep 26Is Virbac SA (EPA:VIRP) Trading At A 22% Discount?
Jul 15Is Now The Time To Put Virbac (EPA:VIRP) On Your Watchlist?
Jun 27Is Virbac (EPA:VIRP) A Risky Investment?
May 27Robust Earnings May Not Tell The Whole Story For Virbac (EPA:VIRP)
Mar 24Are Investors Undervaluing Virbac SA (EPA:VIRP) By 32%?
Mar 12Shareholder Returns
| VIRP | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | 16.1% | 3.3% | 1.6% |
| 1Y | 1.7% | -10.6% | 8.9% |
Return vs Industry: VIRP exceeded the French Pharmaceuticals industry which returned -11.2% over the past year.
Return vs Market: VIRP underperformed the French Market which returned 9.1% over the past year.
Price Volatility
| VIRP volatility | |
|---|---|
| VIRP Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 10.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: VIRP has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: VIRP's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 6,365 | Paul Martingell | corporate.virbac.com |
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. It serves veterinarians, farmers, and pet owners.
Virbac SA Fundamentals Summary
| VIRP fundamental statistics | |
|---|---|
| Market cap | €3.00b |
| Earnings (TTM) | €133.03m |
| Revenue (TTM) | €1.43b |
Is VIRP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIRP income statement (TTM) | |
|---|---|
| Revenue | €1.43b |
| Cost of Revenue | €476.86m |
| Gross Profit | €955.87m |
| Other Expenses | €822.84m |
| Earnings | €133.03m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Jan 15, 2026
| Earnings per share (EPS) | 15.88 |
| Gross Margin | 66.72% |
| Net Profit Margin | 9.29% |
| Debt/Equity Ratio | 27.2% |
How did VIRP perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/22 01:03 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Virbac SA is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laurent Gelebart | BNP Paribas Exane |
| Arnaud Cadart | CIC Market Solutions (ESN) |
| Pierre-Alexandre Désir | Gilbert Dupont |